Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016716 | 0.89 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL5023673 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL5025590 | 0.81 | KDM4E (0.62) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL4573629 | 0.75 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL1849885 | 0.73 | KDM4E (0.76) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL15766209 | 0.73 | KDM4E (0.76) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL15766218 | 0.73 | KDM4E (0.74) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL4928789 | 0.72 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL7251926 | 0.72 | POLB (0.73) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL5023109 | 0.72 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486996-B2 | Aroylfuranes and aroylthiophenes | BASILEA PHARMACEUTICA AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8486996-B2 | Aroylfuranes and aroylthiophenes | BASILEA PHARMACEUTICA AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8486996-B2 | Aroylfuranes and aroylthiophenes | BASILEA PHARMACEUTICA AG (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-1894917-A1 | Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer | Basilea Pharmaceutica AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1894917-A1 | Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer | Basilea Pharmaceutica AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1697336-B1 | AROYLFURANES AND AROYLTHIOPHENES SUITABLE FOR THE TREATMENT OF CANCER | BASILEA PHARMACEUTICA AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060205739-A1 | Aroylfuranes and aroylthiophenes | BASILEA PHARMACEUTICA AG | 2006-09-14 | — | — | US | disclosed |
| EP-1697336-A2 | AROYLFURANES AND AROYLTHIOPHENES SUITABLE FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061476-A2 | AROYLFURANES AND AROYLTHIOPHENES | BASILEA PHARMACEUTICA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205739-A1 | Aroylfuranes and aroylthiophenes | TPMT, APRT, ABAT | KDM4E 823/4885ALDH1A1 308/4885SMN1; SMN2 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.